Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 6th 2018

HIV/AIDS Research Has Positive Impacts Across Other Medical Fields

Jaime Rosenberg

In addition to the advances made in the HIV space, such as antiretroviral therapies and pre-exposure prophylaxis, the years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.

September 5th 2018

Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care

As the oncology landscape continues to rapidly evolve, access to real-time data has become increaisngly important, and technology-based medical startups have made their way to the front of the lines with point-of-care tools that use technology to transform cancer care.

September 4th 2018

Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma

Laura Joszt, MA

Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

September 2nd 2018

Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models

Laura Joszt, MA

As the healthcare system considers alternative payment models that reward high-value care delivery, programs that utilize lay health workers (LHW) may be valuable. A study in JAMA Oncology analyzed whether an LHW program can increase the documentation of patients’ care preferences.

August 31st 2018

What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller

AJMC Staff

A judge tossed a lawsuit brought by pharmaceutical companies to block a California law requiring advance notice of big price increases; the FDA is testing all angiotensin II receptor blockers (ARBs) over a discovered impurity that is linked to cancer; research in monkeys has suggested that an experimental painkiller is effective at easing pain without being addictive.

August 31st 2018

Dr Don Dizon: Discussing Sexual Health Needs With Patients With Cancer

Most oncologists aren’t comfortable discussing sexual health needs with their patients, but there are places where sexual health services for patients with cancer are starting to gain foothold, said Don S. Dizon, MD, FACP, FASCO, director of Women's Cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and associate professor of medicine at The Warren Alpert Medical School of Brown University.

August 31st 2018

Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers

Laura Joszt, MA

A survey of patients in the United Kingdom who were diagnosed with cancer found that patients with blood cancers were the least likely to say they completely understood what was wrong when the doctor explained it. They were also less likely to say that their treatment options were explained before treatment started compared with patients with other cancers.

August 30th 2018

Medicaid Expansion Helped Reduce Disparities Among Different Groups With Cancer

Allison Inserro

The expansion of Medicaid may mitigate health disparities in cancer diagnosis, according to a recent study that found state variation in reductions in the percentage of uninsured patients aged 18 to 64 years diagnosed with cancer. The researchers said that the results have implications for future disparities in state mortality rates, because health insurance coverage is linked to the ability to have better treatment and survival after diagnosis.

August 28th 2018

Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population

Laura Joszt, MA

As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. However, a new study has found that over time, childbearing rates for female survivors of HL have improved to the point of approaching the rates of the general population.

August 25th 2018

Podcast: This Week in Managed Care—Patient-Reported Outcomes With CAR T and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

August 24th 2018

Utilizing Bioinformatics to Determine a Patient's Response to Immunotherapy

Samantha DiGrande

A recent study at Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy discovered a new way to use bioinformatics to determine how a patient’s immune system responds to immunotherapy.

August 24th 2018

This Week in Managed Care: August 24, 2018

This week, the top managed care news included a panel mostly endorsed the use of patient-reported outcomes for coverage of chimeric antigen receptor T-cell therapy; the US Preventive Services Task Force released new recommendations for cervical cancer screening; research found accountable care organization penetration may be changing how physicians work.

August 23rd 2018

NCCN Releases New Guidelines for Rare Cancers During Pregnancy

Samantha DiGrande

Earlier this month, the National Comprehensive Cancer Network (NCCN) released new treatment guidelines for a group of rare cancers that impact women during pregnancy.

August 23rd 2018

CURE Media Group Expands Strategic Alliance Partnership Program With The Biden Cancer Initiative

Sister publication American Journal of Managed Care® will also be a part of this collaboration.

August 22nd 2018

Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy

Laura Joszt, MA

A blood test that tracks the rise and fall of circulating tumor DNA (ctDNA) levels can predict how patients with diffuse large B-cell lymphoma will respond to therapy within days of starting treatment.

August 22nd 2018

Dr Denalee O'Malley Discusses Unique Concerns of Younger Patients With Breast Cancer

Younger, premenopausal patients with breast cancer can have unique issues that providers need to keep in mind, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.

August 22nd 2018

From the Editor-in-Chief: What Happens Next?

Joseph Alvarnas, MD

A letter from our Editor-in-Chief, Joseph Alvarnas, MD.

August 22nd 2018

Survivorship Care Throughout the Cancer Journey

Don Champlain, MHA, RN Lucio Gordan, MD

Leaders at Florida Cancer Specialists discuss the cancer survivorship program they've created to meet the needs of their diverse population of patients.

August 22nd 2018

Conference Coverage: NCCN Policy Summit 2018

Mary Caffrey

August 22nd 2018

AJMCtv® Interviews, August 2018

Mary Caffrey Jaime Rosenberg Samantha DiGrande

August 22nd 2018

Clinical Updates, August 2018

Surabhi Dangi-Garimella, PhD Laura Joszt, MA Kelly Davio Samantha DiGrande

August 21st 2018

EBO 2018: Managed Care Updates

Jaime Rosenberg Laura Joszt, MA Alison Rodriguez

August 21st 2018

CAR T Signaling Differences Could Point the Way to More Targeted Treatments, Study Says

Allison Inserro

The first chimeric antigen receptor (CAR) T-cell therapy was approved just a year ago, changing the face of treatment for certain types of leukemias and lymphomas but carrying with it the downsides of toxicity and cost. A year later, scientists from a major cancer center said that they’ve made headway to discovering more about the T-cell signaling patterns and that understanding more about the biological pathways could help design the next generation of CAR-T treatments.

August 21st 2018

Payment Reform in Cancer Needs to Engage and Reward Patients, Experts Assert

Laura Joszt, MA

Payment reform efforts that don't engage patients are missing out on an opportunity for greater improvements, especially in cancer, where patients face substantial cost sharing.

August 20th 2018

Economic Evaluation of Patient-Centered Care Among Long-Term Cancer Survivors

Jaejin An, BPharm, PhD Adrian Lau, PharmD

Providing patient-centered comprehensive care to long-term cancer survivors may lead to reduced total healthcare expenditures. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.

August 17th 2018

Many Questions to Ask in Setting National Coverage for CAR T Therapies

Allison Inserro

Next week, a CMS committee will hold a day-long meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell immunotherapies, and in Thursday’s New England Journal of Medicine, Peter B. Bach, MD, MAPP, reviewed several strategies open to CMS as it continues to try to determine how to pay for CAR T.

August 16th 2018

PARP Inhibitor Increases PFS Over Chemotherapy in Advanced Breast Cancers, Study Finds

Samantha DiGrande

A recent study found that the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib extended progression-free survival (PFS) and improved quality of life over chemotherapies for patients with metastatic human epidermal growth factor 2-negative breast cancer and mutations in the BRCA 1/2 genes.

August 16th 2018

AI Platform Can Identify Personalized Drug Combinations to Treat Multiple Myeloma

Laura Joszt, MA

A new technology platform utilizing artificial intelligence (AI) could change how drug combinations are designed and help doctors to identify optimal personalized drug combinations for patients with multiple myeloma.

August 16th 2018

Healthcare Costs and Access for Young Adult Cancer Survivors: A Snapshot Post ACA

Michelle S. Landwehr, MPH Samantha E. Watson, MBA Maia Dolphin-Krute, BFA

The Samfund conducted a preliminary investigation into the impact of the Affordable Care Act on young adult cancer survivors’ medical cost burden and access to health care.

August 16th 2018

Survivorship Care in AYA Patients: Battling the Loss to Follow-up

Samantha DiGrande

For insights on this issue, Evidence-Based Oncology™ spoke with Lynda Kwon Beaupin, MD, a pediatric hematologist-oncologist who recently became the director of CanSurvive, the pediatric cancer survivorship program at Johns Hopkins All Children’s Hospital in St. Petersburg, Florida. Beaupin and her colleagues in the Consortium of Adolescent and Young Adult Cancer Centers, which includes oncologists from major cancer centers including Johns Hopkins, are working to address the nuances that come with treating adolescent and young adult cancer patients and looking for ways to increase their quality of life.

...

38 39 40 41 42 43 44 45 46

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions